Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05139238 · ClinicalTrials.gov registry record · Phase 4
Postpartum Hypertension Study
A Phase 4 study of Postpartum Preeclampsia and Hypertensive Emergency, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 104
- Enrollment target
- 1
- Study location
NCT05139238: Recruiting Phase 4 study of Postpartum Preeclampsia and Hypertensive Emergency, sponsored by Columbia University.
NCT05139238 is a Phase 4 study of Postpartum Preeclampsia and Hypertensive Emergency that is actively recruiting participants, run by Columbia University. The registered enrollment target is 104 participants, below the 555-participant average among 5 other Postpartum Preeclampsia trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05139238, a Phase 4 study of Postpartum Preeclampsia and Hypertensive Emergency, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess which blood pressure medication (intravenous labetalol or oral nifedipine) works better in treating severely elevated blood pressure in women who have just delivered a baby.
Primary Outcome
The primary outcome will be time (minutes) interval required to achieve the therapeutic BP goal of \<160 mmHg systolic and \<110 mmHg diastolic.
Conditions Studied
Interventions
- DRUG Labetalol
- DRUG Nifedipine
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2022-07-04 |
| Est. Completion | 2027-12 |
| Phase | Phase 4 |
What NCT05139238 shows while recruiting
NCT05139238 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 555-participant average among 5 other Postpartum Preeclampsia trials with a reported enrollment target (81% lower).
The record links to 4 conditions, with Postpartum Preeclampsia appearing as the primary indexed condition, and to 2 interventions - of which Labetalol is the first listed.
NCT05139238 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05139238 about?
NCT05139238 is a clinical study titled "Postpartum Hypertension Study". The purpose of this study is to assess which blood pressure medication (intravenous labetalol or oral nifedipine) works better in treating severely elevated blood pressure in women who have just delivered a baby.
What is the current status of trial NCT05139238?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 104 participants. The study started on 2022-07-04. Estimated completion is 2027-12.
What conditions does trial NCT05139238 study?
This clinical trial studies the following conditions: Postpartum Preeclampsia, Hypertensive Emergency, Postpartum Pregnancy-Induced Hypertension, Pregnancy-Induced Hypertension in Postpartum.
What interventions are being tested in trial NCT05139238?
The interventions under investigation include: Labetalol (DRUG), Nifedipine (DRUG).
Who is sponsoring clinical trial NCT05139238?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05139238 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postpartum Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
RECRUITING · Phase 4
-
Rhode Island - Statewide Postpartum Hypertension Remote Surveillance
RECRUITING · NA
-
Innovation in Postpartum Care for Women With Hypertensive Disorders of Pregnancy
COMPLETED · NA
-
Management of Postpartum Preeclampsia
COMPLETED · NA
-
Heart Health 4 New Moms: A Randomized Trial in the First Year After Preeclampsia
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI